These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 17262062

  • 41. Autografting for multiple myeloma: a 5-year experience at a single institution.
    Mahendra P, Hood IM, Johnson D, Ethell M, Jestice HK, Scott MA, Barker P, Bass G, Baglin TP, Marcus RE.
    Bone Marrow Transplant; 1995 Dec; 16(6):759-63. PubMed ID: 8750266
    [Abstract] [Full Text] [Related]

  • 42. High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study.
    Meloni G, Capria S, Trasarti S, Ferrazza G, Micozzi A, Petrucci MT, Simone F, Trisolini SM, Mandelli F.
    Bone Marrow Transplant; 2000 Nov; 26(10):1045-9. PubMed ID: 11108301
    [Abstract] [Full Text] [Related]

  • 43. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
    Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P.
    Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
    [Abstract] [Full Text] [Related]

  • 44. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
    Kennedy GA, Butler J, Morton J, Hill G, Western R, Cummings J, Allison R, Durrant S.
    Clin Lab Haematol; 2006 Jun; 28(3):189-97. PubMed ID: 16706936
    [Abstract] [Full Text] [Related]

  • 45. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.
    Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés F, Marin P, Martinez C, Rovira M, Urbano-Ispizua A, Carreras E, Montserrat E.
    Bone Marrow Transplant; 2004 Jan; 33(1):61-4. PubMed ID: 14704657
    [Abstract] [Full Text] [Related]

  • 46. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Bladé J, San Miguel JF, Sanz MA, de la Rubia J.
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [Abstract] [Full Text] [Related]

  • 47. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT, Waller EK, Leong T, Heffner LT, Redei I, Langston AA, Lonial S.
    Cancer; 2006 May 15; 106(10):2171-80. PubMed ID: 16598756
    [Abstract] [Full Text] [Related]

  • 48. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, Kim DH, Sohn SK, Lee JJ, Suh C.
    Biol Blood Marrow Transplant; 2006 Aug 15; 12(8):837-44. PubMed ID: 16864054
    [Abstract] [Full Text] [Related]

  • 49. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
    Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L, Adam Z, Mayer J, Vorlicek J.
    Bone Marrow Transplant; 2005 Jan 15; 35(2):159-64. PubMed ID: 15543200
    [Abstract] [Full Text] [Related]

  • 50. [Autologous peripheral blood stem cell transplantation for Japanese multiple myeloma patients: results of a feasibility study].
    Nakamura Y, Sakamaki H, Mukai H, Kojima H, Tomiyama J, Mori S, Hiruma K, Nakamura N, Toyota S, Hamaguchi H, Dans K, Mitani K, Saito K.
    Rinsho Ketsueki; 2004 Jul 15; 45(7):524-9. PubMed ID: 15359911
    [Abstract] [Full Text] [Related]

  • 51. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.
    J Clin Oncol; 2009 Apr 10; 27(11):1788-93. PubMed ID: 19273705
    [Abstract] [Full Text] [Related]

  • 52. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
    Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB.
    Biol Blood Marrow Transplant; 2009 Nov 10; 15(11):1447-54. PubMed ID: 19822305
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
    Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J.
    Bone Marrow Transplant; 2002 Nov 10; 30(10):673-9. PubMed ID: 12420206
    [Abstract] [Full Text] [Related]

  • 56. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
    Benson DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS.
    Leuk Res; 2007 Aug 10; 31(8):1069-75. PubMed ID: 17070906
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun 10; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 60. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
    Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, Narni F, Carubelli A, Masini L, Catalano L, Fiacchini M, de Vivo A, Gozzetti A, Lazzaro A, Tura S, Baccarani M.
    J Clin Oncol; 2007 Jun 10; 25(17):2434-41. PubMed ID: 17485707
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.